Millennium Management’s Travere Therapeutics TVTX Stock Holding History

Millennium Management’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-15,800	Closed	-$141K	–	6553
2023 Q3	$141K	Buy	+15,800	New	+$223K	﹤0.01%	5236
2022 Q4	–	Sell	-100,000	Closed	-$2.46M	–	7067
2022 Q3	$2.46M	Buy	+100,000	New	+$2.58M	﹤0.01%	3559
2019 Q4	–	Sell	-50,000	Closed	-$579K	–	4646
2019 Q3	$579K	Hold	50,000	–	–	﹤0.01%	3163
2019 Q2	$1M	Buy	+50,000	New	+$987K	﹤0.01%	2811
2016 Q4	–	Sell	-243,500	Closed	-$5.45M	–	3750
2016 Q3	$5.45M	Buy	243,500 +183,500	+306%	+$3.49M	0.01%	1285
2016 Q2	$1.07M	Buy	+60,000	New	+$971K	﹤0.01%	2129

Other funds holding TVTX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Millennium Management's TVTX Position: Q1 2026 in Review

Millennium Management sold out of Travere Therapeutics (TVTX) in Q1 2026, closing a stake of 136,065 shares — an estimated $4.07M sold.

Millennium Management first reported a position in TVTX in Q1 2014 and held it in 45 quarters. The position peaked at $30M in Q3 2023. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

Millennium Management reported no remaining Travere Therapeutics position as of Q1 2026 after selling out during the quarter.
Millennium Management sold 136,065 Travere Therapeutics shares in Q1 2026, an estimated $4.07M.
Millennium Management first reported a position in Travere Therapeutics in Q1 2014 and held it in 45 quarters.
Millennium Management's Travere Therapeutics position peaked at $30M in Q3 2023.
260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.